Volume 6 Issue 7, July 2022

The T-cell receptors of tumour-antigen-specific T cells can be rapidly detected and cloned by a system leveraging the activation of T cells via cis interactions.

Masking interleukin-12 with a domain of the interleukin-12 receptor via a linker cleavable by tumour-associated proteases eliminates systemic immune-related adverse events and triggers potent therapeutic effects in mice bearing immunologically cold tumours.

T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein from Helicobacter pylori trigger endogenous bystander T-cell responses against solid cancers.

Synthetically generated and clonally expanded libraries of immune cells displaying diverse repertoires of chimaeric antigen receptors lead to long-lasting and potent antitumour responses in mouse models of epithelial tumours.

Screening a large barcoded library of unique CD19-specific chimaeric antigen receptors with diverse intracellular domains allows for the discovery of receptors that elicit enhanced antitumoural functions.

The encapsulation of antibiotics in glucosylated polymeric nanoparticles that are readily absorbed by the proximal small intestine improves the bioavailability of the antibiotics and limits their exposure to flora in the large intestine.

Mesenchymal stromal cells with their nuclei removed by density-gradient centrifugation and displaying chemoattractant receptors and endothelial-cell-binding molecules function as effective vehicles for the delivery of therapeutics to diseased tissue.

Tumour vaccines consisting of outer membrane vesicles bearing a specific tumour antigen and produced in the intestine by ingested genetically engineered bacteria generate long-term antitumour immunity in mice.

A strain of Lactococcus lactis engineered to altruistically degrade β-lactam antibiotics through the secretion and extracellular assembly of a heterodimeric β-lactamase prevented dysbiosis in the gut of mice treated with ampicillin.